Open AccessThe use of Ingaron® in the treatment of chronic viral hepatitis B
Author(s) -
Ekaterina A. Zaytseva,
Зайцева Екатерина Александровна,
Л. Л. Попова,
Попова Лариса Леонидовна,
D.Yu. Konstantinov,
Константинов Дмитрий Юрьевич
Publication year - 2020
Publication title -
aspirantskij vestnik povolžʹâ
Language(s) - English
Resource type - Journals
eISSN - 2410-3764
pISSN - 2072-2354
DOI - 10.17816/2072-2354.2020.20.3.63-67
Subject(s) - entecavir , tolerability , medicine , antiviral treatment , antiviral therapy , regimen , chronic hepatitis , viral hepatitis , virology , viral load , gastroenterology , immunology , lamivudine , adverse effect , virus
The possibility of antiviral therapy with the direct antiviral drugs Entecavir and Ingaron, as an antiviral and immunomodulating therapy, was studied in patients with the recurrent chronic viral hepatitis B. The study showed the applicability of this treatment regimen, due to the increase in the number of patients with SVR, high tolerability and the absence of clinically significant side effects.